The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

ABSTRACT: Improved understanding of the mechanisms of lymphomagenesis has resulted in a surge of development for new targeted agents. An impressive number of biological agents targeting different steps in the pathways of tumor proliferation, survival and apoptosis have become available. The management of patients with indolent non-Hodgkin lymphomas (iNHLs) is rapidly transforming with incorporation of those targeted biological agents into the front-line and relapsed/refractory setting. This review highlights several categories of novel biological agents and will discuss their potential role in the contemporary management of patients with iNHLs.

SUBMITTER: Wang TP 

PROVIDER: S-EPMC5703116 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature